Todd Bennett Net Worth

The estimated Net Worth of Todd C. Bennett is at least $6.66 Million dollars as of 25 February 2021. Mr. Bennett owns over 121,507 units of Luminex Corp stock worth over $5,757,124 and over the last 8 years he sold LMNX stock worth over $0. In addition, he makes $900,021 as Senior Vice President - Global Sales and Customer Operations at Luminex Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Bennett LMNX stock SEC Form 4 insiders trading

Todd has made over 2 trades of the Luminex Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 121,507 units of LMNX stock worth $2,319,569 on 25 February 2021.

The largest trade he's ever made was exercising 121,507 units of Luminex Corp stock on 25 February 2021 worth over $2,319,569. On average, Todd trades about 13,749 units every 113 days since 2017. As of 25 February 2021 he still owns at least 155,640 units of Luminex Corp stock.

You can see the complete history of Mr. Bennett stock trades at the bottom of the page.

Todd Bennett biography

Todd C. Bennett serves as Senior Vice President - Global Sales and Customer Operations of the Company. Mr. Bennett joined the Company in October 2012 as General Manager, Americas. Mr. Bennett was promoted to Vice President, Global Sales and Customer Operations in July 2015 and to Senior Vice President, Global Sales and Customer Operations in November 2016. From January 2007 through March 2012, Mr. Bennett was the Vice President of Sales and then promoted to Vice President of Commercial Operations at Immucor, Inc., a provider of transfusion and transplantation products, where he was responsible for Commercial Operations (Sales, Global Marketing, Customer Service functions). Prior to Immucor, Mr. Bennett held various commercial leadership roles at Roche Diagnostics and Abbott Laboratories dating to 1994. Mr. Bennett holds a B.S. in Business Administration with an emphasis in finance from the Max M. Fisher College of Business at The Ohio State University in Columbus, Ohio.

What is the salary of Todd Bennett?

As the Senior Vice President - Global Sales and Customer Operations of Luminex Corp, the total compensation of Todd Bennett at Luminex Corp is $900,021. There are 3 executives at Luminex Corp getting paid more, with Nachum Shamir having the highest compensation of $3,362,140.

How old is Todd Bennett?

Todd Bennett is 50, he's been the Senior Vice President - Global Sales and Customer Operations of Luminex Corp since 2016. There are 13 older and 1 younger executives at Luminex Corp. The oldest executive at Luminex Corp is Thomas Erickson, 69, who is the Independent Director.

Insiders trading at Luminex Corp

Over the last 21 years, insiders at Luminex Corp have traded over $55,627,864 worth of Luminex Corp stock and bought 685,936 units worth $10,423,148 . The most active insiders traders include G Walter Ii Loewenbaum, Douglas C Bryant und Laurence E Hirsch. On average, Luminex Corp executives and independent directors trade stock every 26 days with the average trade being worth of $888,944. The most recent stock trade was executed by Harriss T Currie on 1 March 2021, trading 5,325 units of LMNX stock currently worth $97,235.

What does Luminex Corp do?

The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Complete history of Mr. Bennett stock trades at Luminex Corp

Luminex Corp executives and stock owners

Luminex Corp executives and other stock owners filed with the SEC include:

• Nachum Shamir,
  President, Chief Executive Officer, Director
• Harriss Currie,
  Chief Financial Officer, Senior Vice President - Finance, Treasurer
• Richard Rew,
  Senior Vice President, General Counsel and Corporate Secretary
• Todd Bennett,
  Senior Vice President - Global Sales and Customer Operations
• Randall Myers,
  Senior Vice President - Global Manufacturing and Quality
• Kenneth Samet,
  Independent Director
• Kevin McNamara,
  Independent Director
• Jimmy Kever,
  Independent Director
• Edward Ogunro,
  Lead Independent Director
• Thomas Erickson,
  Independent Director
• Stephen Eck,
  Independent Director
• Dijuana Lewis,
  Independent Director
• Eric Shapiro,
  Senior Vice President - Global Marketing
• Nancy Fairchild,
  Senior Vice President - Human Resources
• Chuck Collins,
  Senior Vice President - Research and Development
• Robert J Cresci,
  Director
• Tadd S. Lazarus,
  SVP, Chief Medical Officer
• Jay B Johnston,
  Director
• Russell S Bradley,
  VP, Strategic Planning and Bus
• G Walter Ii Loewenbaum,
  Director
• Jim D Kever,
  Director
• Gregory J Gosch,
  Vice President - Marketing
• Charles J. Collins,
  SR VP, R&D - US
• John C Carrano,
  VP, Research & Development
• J Stark Phd Thompson,
  Director
• Douglas C Bryant,
  EVP, Chief Operating Officer
• James W Jacobson,
  VP, Research & Development
• Oliver H Meek,
  VP, Manufacturing
• Randel S Martin,
  VP, Marketing/Sales
• Kristi M Richburg,
  Controller
• G Walter Ii Loewenbaum,
  Director
• C Thomas Caskey,
  Director
• Laurence E Hirsch,
  Director
• Fred C Jr Goad,
  Director
• Jeremy K Bridge Cook,
  VP, Luminex Molecular Diagn
• Michael F Pintek,
  SVP Operations
• Patrick J Balthrop,
  President, Chief Exec. Officer
• Timothy R Dehne,
  VP, Systems R&D
• David S Reiter,
  General Counsel & Secretary
• Gerard Vaillant,
  Director